Increasing FABP1 expression in HepG2 cells results in increased uptake of radiolabeled oleic acid by 38% and 78%, respectively [57,58], and downregulation of FABP1 levels has a therapeutic effect in metabolic diseases [48,59]. Here, FABP1 is linked to metabolic disease.